<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287402</url>
  </required_header>
  <id_info>
    <org_study_id>AO-128/OCT-910</org_study_id>
    <secondary_id>JapicCTI-101004</secondary_id>
    <secondary_id>U1111-1163-1618</secondary_id>
    <nct_id>NCT02287402</nct_id>
  </id_info>
  <brief_title>Postmarketing Clinical Study on AO-128</brief_title>
  <official_title>Postmarketing Clinical Study on AO-128</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of open-label study is to evaluate the efficacy and safety of AO-128 (Voglibose)
      0.6 mg/day in patients with impaired glucose tolerance (IGT) who had been non-responsive to
      diet therapy and exercise therapy, and follow up the progress after the end of treatment in
      patients who was assessed as normoglycemic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Î±-glucosidase inhibitor voglibose was developed by Takeda Pharmaceutical Co. Ltd and is
      one of the most commonly used oral antidiabetic agents in Japan. Voglibose is used as
      first-line treatment for improvement of postprandial hyperglycemia in diabetic patients with
      inadequate response to diet and exercise therapy and as add-on treatment to other oral
      antidiabetic drugs and insulin. In 2009, voglibose was approved in Japan for the management
      of prediabetes (IGT).

      This study was a single-group, multi-center, open-label study. The study period consisted of
      a screening period of 1 week or less, a treatment period of 96 weeks or more, and a follow-up
      period of 48 weeks. However, if a patient was assessed as having type 2 diabetes mellitus or
      normoglycemia, the treatment period was to be ended, and only those assessed as normoglycemic
      were to proceed to follow-up. Follow-up was also to be terminated if patients were assessed
      as having IGT or type 2 diabetes mellitus during follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Diabetic Status in the Treatment Period (Type 2 Diabetes Mellitus, Normoglycemia, or Impaired Glucose Tolerance (IGT)</measure>
    <time_frame>Treatment period: Up to 122 weeks. Treatment was to be ended when patients were assessed as Type 2 Diabetes Mellitus or normoglycemic.</time_frame>
    <description>Frequency tabulations of the &quot;assessment of diabetic status in the treatment period (Type 2 Diabetes mellitus, normoglycemia, or IGT)&quot; were prepared in the &quot;Full Analysis Set&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Diabetic Status in Follow-up (Type 2 Diabetes Mellitus, Normoglycemia, or IGT)</measure>
    <time_frame>Follow-up at Week 12, 24, 36, and 48</time_frame>
    <description>Frequency tabulations of the &quot;assessment of diabetic status in the follow-up (Type 2 Diabetes mellitus, normoglycemia, or IGT)&quot; were prepared in patients who proceeded to the follow-up in the &quot;Full Analysis Set&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression to Type 2 Diabetes Mellitus in the Treatment Period Calculated by the Kaplan-Meier Method</measure>
    <time_frame>Day 168, 336, 504, and 672</time_frame>
    <description>The cumulative progression rate (percentage of participants) was calculated by the Kaplan-Meier method for the &quot;time to progression to Type 2 Diabetes mellitus in the treatment period&quot; in the &quot;Full Analysis Set&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression to Type 2 Diabetes Mellitus in the Treatment Period Calculated Using the Cumulative Incidence Function</measure>
    <time_frame>Day 168, 336, 504, and 672</time_frame>
    <description>The cumulative progression rate (percentage of participants) was calculated using the cumulative incidence function for the &quot;time to progression to type 2 diabetes mellitus in the treatment period&quot; in the &quot;Full Analysis Set&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement to Normoglycemia in the Treatment Period Calculated by the Kaplan-Meier Method</measure>
    <time_frame>Day 168, 336, 504, and 672</time_frame>
    <description>The cumulative progression rate (percentage of participants) was calculated by the Kaplan-Meier method for the &quot;time to improvement to normoglycemia in the treatment period&quot; in the &quot;Full Analysis Set&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Improvement to Normoglycemia in the Treatment Period Measured Values by the Cumulative Incidence Function</measure>
    <time_frame>Day 168, 336, 504, and 672</time_frame>
    <description>The cumulative progression rate (percentage of participants) was calculated using the cumulative incidence function for the &quot;time to improvement to normoglycemia in the treatment period&quot; in the &quot;Full Analysis Set&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-Hour Plasma Glucose During 75 g Oral Glucose Tolerance Test (OGTT)</measure>
    <time_frame>Week 0, 24, 48, 72, 96, 120, and the end of the treatment period</time_frame>
    <description>Summary statistics were calculated at each assessment time point for the 2-hour plasma glucose during 75 g OGTT in the &quot;Full Analysis Set.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-Hour Plasma Glucose During 75 g OGTT at Follow-up</measure>
    <time_frame>Follow-up at week 0, 12, 24, 36, and 48</time_frame>
    <description>Summary statistics were calculated at each assessment time point for the 2-hour plasma glucose during 75 g OGTT in participants who proceeded to the follow-up in the &quot;Full Analysis Set.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Week 0, 12, 24, 48, 72, 96, 120, and the end of the treatment period.</time_frame>
    <description>Summary statistics were calculated at each assessment time point for the HbA1c in the &quot;Full Analysis Set.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c at Follow-up</measure>
    <time_frame>Follow-up at Week 0, 12, 24, 36, and 48</time_frame>
    <description>Summary statistics were calculated at each assessment time point for the HbA1c in patients who proceeded to the follow-up in the &quot;Full Analysis Set.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>Week 0, 12, 24, 48, 72, 96, 120, and the end of the treatment period</time_frame>
    <description>Summary statistics were calculated at each assessment time point for the body weight in the &quot;Full Analysis Set.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight at Follow-up</measure>
    <time_frame>Follow-up at Week 0, 12, 24, 36, and 48</time_frame>
    <description>Summary statistics were calculated at each assessment time point for the HbA1c in patients who proceeded to the follow-up in the &quot;Full Analysis Set.&quot;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Impaired Glucose Tolerance (IGT)</condition>
  <arm_group>
    <arm_group_label>AO-128 0.6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AO-128</intervention_name>
    <description>AO-128 tablet</description>
    <arm_group_label>AO-128 0.6 mg</arm_group_label>
    <other_name>Voglibose</other_name>
    <other_name>BASEN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients on diet therapy and exercise therapy for 3 to 6 months prior to the start of
             screening, with baseline (fasting ) plasma glucose &lt; 126 mg/dL and 2-hour plasma
             glucose of 140 to 199 mg/dL (revised WHO criteria) during a 75 g oral glucose
             tolerance test (OGTT) in the screening period

          2. Patients meeting any of 1 through 4 below:

               -  1) Comorbid hypertension or high normal blood pressure

               -  2) Comorbid dyslipidemia

               -  3) Comorbid obesity

               -  4) Patients with up to a second-degree family history of type 2 diabetes mellitus

          3. Patients with HbA1c &lt; 6.5% in the screening period

          4. Male or female patients at least 20 years of age at the time informed consent was
             obtained

          5. Treatment category: Outpatient

        Exclusion Criteria:

          1. Patients previously diagnosed with diabetes mellitus.

          2. Patients with apparent impaired glucose metabolism or with a disease or condition
             potentially involving impaired glucose metabolism.

          3. Patients with serious hepatic impairment.

          4. Patients with serious renal impairment.

          5. Patients with serious cardiac, cerebrovascular, pancreatic, hematologic, or other
             disease.

          6. Patients with a history of intestinal obstruction or a history of laparotomy within 6
             months (24 weeks) before the start of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2014</study_first_submitted>
  <study_first_submitted_qc>November 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <results_first_submitted>December 9, 2014</results_first_submitted>
  <results_first_submitted_qc>April 8, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2015</results_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 30 investigative sites in Japan from 9 March 2010 to 15 November 2012.</recruitment_details>
      <pre_assignment_details>Participants with impaired glucose tolerance (IGT) who had been non-responsive to diet therapy and exercise therapy receive one AO-128 0.2 mg tablet orally 3 times a day before meals.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AO-128 0.6 mg</title>
          <description>One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106">64 participants who completed the Treatment Period did not continue to Follow-up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AO-128 0.6 mg</title>
          <description>One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="197"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â¥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Diabetic Status in the Treatment Period (Type 2 Diabetes Mellitus, Normoglycemia, or Impaired Glucose Tolerance (IGT)</title>
        <description>Frequency tabulations of the &quot;assessment of diabetic status in the treatment period (Type 2 Diabetes mellitus, normoglycemia, or IGT)&quot; were prepared in the &quot;Full Analysis Set&quot;.</description>
        <time_frame>Treatment period: Up to 122 weeks. Treatment was to be ended when patients were assessed as Type 2 Diabetes Mellitus or normoglycemic.</time_frame>
        <population>Full Analysis Set - All participants who received at least 1 dose of open-label study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AO-128 0.6 mg</title>
            <description>One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Diabetic Status in the Treatment Period (Type 2 Diabetes Mellitus, Normoglycemia, or Impaired Glucose Tolerance (IGT)</title>
          <description>Frequency tabulations of the &quot;assessment of diabetic status in the treatment period (Type 2 Diabetes mellitus, normoglycemia, or IGT)&quot; were prepared in the &quot;Full Analysis Set&quot;.</description>
          <population>Full Analysis Set - All participants who received at least 1 dose of open-label study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 2 Diabetes mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Diabetic Status in Follow-up (Type 2 Diabetes Mellitus, Normoglycemia, or IGT)</title>
        <description>Frequency tabulations of the &quot;assessment of diabetic status in the follow-up (Type 2 Diabetes mellitus, normoglycemia, or IGT)&quot; were prepared in patients who proceeded to the follow-up in the &quot;Full Analysis Set&quot;.</description>
        <time_frame>Follow-up at Week 12, 24, 36, and 48</time_frame>
        <population>Participants from the Full Analysis Set, all participants who received at least 1 dose of open-label study drug, and continued to Follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>AO-128 0.6 mg</title>
            <description>One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Diabetic Status in Follow-up (Type 2 Diabetes Mellitus, Normoglycemia, or IGT)</title>
          <description>Frequency tabulations of the &quot;assessment of diabetic status in the follow-up (Type 2 Diabetes mellitus, normoglycemia, or IGT)&quot; were prepared in patients who proceeded to the follow-up in the &quot;Full Analysis Set&quot;.</description>
          <population>Participants from the Full Analysis Set, all participants who received at least 1 dose of open-label study drug, and continued to Follow-up.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Type 2 Diabetes mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression to Type 2 Diabetes Mellitus in the Treatment Period Calculated by the Kaplan-Meier Method</title>
        <description>The cumulative progression rate (percentage of participants) was calculated by the Kaplan-Meier method for the &quot;time to progression to Type 2 Diabetes mellitus in the treatment period&quot; in the &quot;Full Analysis Set&quot;.</description>
        <time_frame>Day 168, 336, 504, and 672</time_frame>
        <population>Full Analysis Set - All participants who received at least 1 dose of open-label study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AO-128 0.6 mg</title>
            <description>One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression to Type 2 Diabetes Mellitus in the Treatment Period Calculated by the Kaplan-Meier Method</title>
          <description>The cumulative progression rate (percentage of participants) was calculated by the Kaplan-Meier method for the &quot;time to progression to Type 2 Diabetes mellitus in the treatment period&quot; in the &quot;Full Analysis Set&quot;.</description>
          <population>Full Analysis Set - All participants who received at least 1 dose of open-label study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 336</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 504</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 672</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression to Type 2 Diabetes Mellitus in the Treatment Period Calculated Using the Cumulative Incidence Function</title>
        <description>The cumulative progression rate (percentage of participants) was calculated using the cumulative incidence function for the &quot;time to progression to type 2 diabetes mellitus in the treatment period&quot; in the &quot;Full Analysis Set&quot;.</description>
        <time_frame>Day 168, 336, 504, and 672</time_frame>
        <population>Full Analysis Set - All participants who received at least 1 dose of open-label study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AO-128 0.6 mg</title>
            <description>One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression to Type 2 Diabetes Mellitus in the Treatment Period Calculated Using the Cumulative Incidence Function</title>
          <description>The cumulative progression rate (percentage of participants) was calculated using the cumulative incidence function for the &quot;time to progression to type 2 diabetes mellitus in the treatment period&quot; in the &quot;Full Analysis Set&quot;.</description>
          <population>Full Analysis Set - All participants who received at least 1 dose of open-label study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 336</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 504</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 672</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Improvement to Normoglycemia in the Treatment Period Calculated by the Kaplan-Meier Method</title>
        <description>The cumulative progression rate (percentage of participants) was calculated by the Kaplan-Meier method for the &quot;time to improvement to normoglycemia in the treatment period&quot; in the &quot;Full Analysis Set&quot;.</description>
        <time_frame>Day 168, 336, 504, and 672</time_frame>
        <population>Full Analysis Set - All participants who received at least 1 dose of open-label study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AO-128 0.6 mg</title>
            <description>One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement to Normoglycemia in the Treatment Period Calculated by the Kaplan-Meier Method</title>
          <description>The cumulative progression rate (percentage of participants) was calculated by the Kaplan-Meier method for the &quot;time to improvement to normoglycemia in the treatment period&quot; in the &quot;Full Analysis Set&quot;.</description>
          <population>Full Analysis Set - All participants who received at least 1 dose of open-label study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 336</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 504</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 672</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Improvement to Normoglycemia in the Treatment Period Measured Values by the Cumulative Incidence Function</title>
        <description>The cumulative progression rate (percentage of participants) was calculated using the cumulative incidence function for the &quot;time to improvement to normoglycemia in the treatment period&quot; in the &quot;Full Analysis Set&quot;.</description>
        <time_frame>Day 168, 336, 504, and 672</time_frame>
        <population>Full Analysis Set - All participants who received at least 1 dose of open-label study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AO-128 0.6 mg</title>
            <description>One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Improvement to Normoglycemia in the Treatment Period Measured Values by the Cumulative Incidence Function</title>
          <description>The cumulative progression rate (percentage of participants) was calculated using the cumulative incidence function for the &quot;time to improvement to normoglycemia in the treatment period&quot; in the &quot;Full Analysis Set&quot;.</description>
          <population>Full Analysis Set - All participants who received at least 1 dose of open-label study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 336</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 504</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 672</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-Hour Plasma Glucose During 75 g Oral Glucose Tolerance Test (OGTT)</title>
        <description>Summary statistics were calculated at each assessment time point for the 2-hour plasma glucose during 75 g OGTT in the &quot;Full Analysis Set.&quot;</description>
        <time_frame>Week 0, 24, 48, 72, 96, 120, and the end of the treatment period</time_frame>
        <population>Full Analysis Set - All participants who received at least 1 dose of open-label study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AO-128 0.6 mg</title>
            <description>One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.</description>
          </group>
        </group_list>
        <measure>
          <title>2-Hour Plasma Glucose During 75 g Oral Glucose Tolerance Test (OGTT)</title>
          <description>Summary statistics were calculated at each assessment time point for the 2-hour plasma glucose during 75 g OGTT in the &quot;Full Analysis Set.&quot;</description>
          <population>Full Analysis Set - All participants who received at least 1 dose of open-label study drug.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.7" spread="17.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.0" spread="34.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.2" spread="36.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.6" spread="36.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.6" spread="33.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.2" spread="31.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The end of the treatment period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.8" spread="37.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-Hour Plasma Glucose During 75 g OGTT at Follow-up</title>
        <description>Summary statistics were calculated at each assessment time point for the 2-hour plasma glucose during 75 g OGTT in participants who proceeded to the follow-up in the &quot;Full Analysis Set.&quot;</description>
        <time_frame>Follow-up at week 0, 12, 24, 36, and 48</time_frame>
        <population>Participants from the Full Analysis Set, all participants who received at least 1 dose of open-label study drug, and continued to Follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>AO-128 0.6 mg</title>
            <description>One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.</description>
          </group>
        </group_list>
        <measure>
          <title>2-Hour Plasma Glucose During 75 g OGTT at Follow-up</title>
          <description>Summary statistics were calculated at each assessment time point for the 2-hour plasma glucose during 75 g OGTT in participants who proceeded to the follow-up in the &quot;Full Analysis Set.&quot;</description>
          <population>Participants from the Full Analysis Set, all participants who received at least 1 dose of open-label study drug, and continued to Follow-up.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Follow-up at Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.4" spread="15.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.3" spread="35.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.9" spread="29.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up at Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.9" spread="18.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.3" spread="20.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin A1c (HbA1c)</title>
        <description>Summary statistics were calculated at each assessment time point for the HbA1c in the &quot;Full Analysis Set.&quot;</description>
        <time_frame>Week 0, 12, 24, 48, 72, 96, 120, and the end of the treatment period.</time_frame>
        <population>Full Analysis Set - All participants who received at least 1 dose of open-label study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AO-128 0.6 mg</title>
            <description>One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1c (HbA1c)</title>
          <description>Summary statistics were calculated at each assessment time point for the HbA1c in the &quot;Full Analysis Set.&quot;</description>
          <population>Full Analysis Set - All participants who received at least 1 dose of open-label study drug.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.45" spread="0.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.35" spread="0.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.30" spread="0.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.37" spread="0.317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.34" spread="0.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.41" spread="0.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.45" spread="0.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The end of the treatment period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.35" spread="0.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c at Follow-up</title>
        <description>Summary statistics were calculated at each assessment time point for the HbA1c in patients who proceeded to the follow-up in the &quot;Full Analysis Set.&quot;</description>
        <time_frame>Follow-up at Week 0, 12, 24, 36, and 48</time_frame>
        <population>Participants from the Full Analysis Set, all participants who received at least 1 dose of open-label study drug, and continued to Follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>AO-128 0.6 mg</title>
            <description>One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c at Follow-up</title>
          <description>Summary statistics were calculated at each assessment time point for the HbA1c in patients who proceeded to the follow-up in the &quot;Full Analysis Set.&quot;</description>
          <population>Participants from the Full Analysis Set, all participants who received at least 1 dose of open-label study drug, and continued to Follow-up.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Follow-up at Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" spread="0.292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.27" spread="0.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.26" spread="0.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up at Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.20" spread="0.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" spread="0.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight</title>
        <description>Summary statistics were calculated at each assessment time point for the body weight in the &quot;Full Analysis Set.&quot;</description>
        <time_frame>Week 0, 12, 24, 48, 72, 96, 120, and the end of the treatment period</time_frame>
        <population>Full Analysis Set - All participants who received at least 1 dose of open-label study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>AO-128 0.6 mg</title>
            <description>One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight</title>
          <description>Summary statistics were calculated at each assessment time point for the body weight in the &quot;Full Analysis Set.&quot;</description>
          <population>Full Analysis Set - All participants who received at least 1 dose of open-label study drug.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.74" spread="13.708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.74" spread="13.659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.91" spread="13.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.25" spread="13.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.03" spread="13.955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.25" spread="14.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.82" spread="14.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The end of the treatment period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.96" spread="13.892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight at Follow-up</title>
        <description>Summary statistics were calculated at each assessment time point for the HbA1c in patients who proceeded to the follow-up in the &quot;Full Analysis Set.&quot;</description>
        <time_frame>Follow-up at Week 0, 12, 24, 36, and 48</time_frame>
        <population>Participants from the Full Analysis Set, all participants who received at least 1 dose of open-label study drug, and continued to Follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>AO-128 0.6 mg</title>
            <description>One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight at Follow-up</title>
          <description>Summary statistics were calculated at each assessment time point for the HbA1c in patients who proceeded to the follow-up in the &quot;Full Analysis Set.&quot;</description>
          <population>Participants from the Full Analysis Set, all participants who received at least 1 dose of open-label study drug, and continued to Follow-up.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Follow-up at Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.60" spread="13.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.76" spread="13.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.87" spread="11.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up at Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.13" spread="11.754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.72" spread="13.844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of open-label study drug until the day of the last dose of open-label study drug.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>AO-128 0.6 mg</title>
          <description>One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Laryngeal cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hitoshi Onouchi</name_or_title>
      <organization>Japan Development Center, Pharmaceutical Development Division, Takeda Pharmaceutical Company Limited</organization>
      <phone>+81-6-6204-5116</phone>
      <email>hitoshi.onouchi@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

